TScan Therapeutics, Inc.

TCRX

TScan Therapeutics, Inc.

TCRX

Insider Sentiment (TTM):

Last Purchase:2025-12-23Last Sale:2024-08-23Shares Purchased (TTM):6,232Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:31,888,948Shares Outstanding:129,913,376Institutional Ownership Pct.:24.55%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Voting Common Stock	-	61	4	-4	0	4	4	45	-39	44	0	4
Nonvoting Common Stock	-	4	4	-4	0	4	4	0	0	4	4	0
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	100	128	152	170	169	154	179	133	242	141	133	155
Marketable Securities Current	-	-	-	15	49	98	111	138	56	22	59	60
Prepaid Expense And Other Assets Current	4	5	5	4	3	3	3	3	2	2	2	2
Assets Current	104	133	157	188	221	255	293	274	300	165	194	218
Property Plant And Equipment Net	8	8	9	9	10	8	7	7	8	7	8	9
Operating Lease Right Of Use Asset	54	56	58	59	61	63	64	60	61	62	63	59
Restricted Cash Noncurrent	5	5	5	5	5	5	5	5	5	5	5	5
Deposits Assets Noncurrent	0	0	0	0	2	2	2	2	2	2	2	2
Assets	171	202	229	262	299	333	371	348	375	241	272	291
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	2	1	6	5	5	4	4	3	2	2	3
Accrued Liabilities And Other Liabilities	8	9	8	11	13	10	15	11	11	9	11	9
Operating Lease Liability Current	8	7	7	7	6	5	5	4	4	3	3	4
Deferred Revenue Current	1	2	3	5	8	10	12	10	11	10	10	15
Long Term Debt Current	-	-	-	-	-	-	-	-	10	7	3	1
Liabilities Current	31	20	19	29	31	30	36	29	39	31	30	33
Deferred Revenue Noncurrent	-	-	-	-	-	1	1	4	4	5	6	8
Operating Lease Liability Noncurrent	50	52	54	56	58	60	61	56	57	58	59	53
Long Term Debt Noncurrent	21	33	33	32	32	32	32	31	20	23	27	29
Other Liabilities Noncurrent	-	-	-	0	0	0	0	0	-	-	-	0
Liabilities	102	105	106	118	122	123	130	119	120	118	121	122
Stockholders Equity
Preferred Stock Value	-	-	-	0	0	0	0	0	0	0	0	-
Additional Paid In Capital Common Stock	633	630	628	626	623	619	616	568	565	401	398	397
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	0	-0	-0	0	-	-	-	-	-
Retained Earnings Accumulated Deficit	-564	-534	-505	-482	-446	-409	-375	-339	-309	-278	-248	-228
Stockholders Equity	69	97	123	144	177	210	241	229	255	123	151	169
Liabilities And Stockholders Equity	171	202	229	262	299	333	371	348	375	241	272	291
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	-
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-13.60%	-22.48%	-36.48%	-	-	-	-	-	-	-	-	-
2025	5.15%	2.94%	41.91%	14.37%	26.35%	16.17%	-9.24%	-14.29%	-14.29%	-8.43%	16.67%	-1.85%
2024	4.62%	-28.71%	-16.23%	-7.50%	-8.17%	-17.50%	-17.16%	-43.45%	-52.58%	-29.69%	-16.67%	-28.12%
2023	-	-	-	-	-	-	50.35%	35.27%	16.47%	11.05%	2.38%	17.62%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.37	6.65	8.41	6.44	7.06	8.55	8.14	9.56	7.77	5.23	6.51	6.56
Quick Ratio	3.23	6.41	8.15	6.32	6.96	8.44	8.07	9.46	7.72	5.17	6.44	6.50
Working Capital	73.44M	112.80M	138.51M	158.96M	189.81M	225.02M	256.77M	245.43M	260.96M	133.24M	164.42M	184.42M
Leverage & Debt
Debt to Equity	1.48	1.08	0.86	0.82	0.69	0.58	0.54	0.52	0.47	0.96	0.80	0.72
Interest Coverage TTM	-43.22	-46.31	-49.05	-52.15	-46.38	-41.42	-36.91	-32.11	-29.80	-27.14	-24.86	-23.38
Debt Ratio	0.60	0.52	0.46	0.45	0.41	0.37	0.35	0.34	0.32	0.49	0.45	0.42
Efficiency & Turnover
Asset Turnover TTM	0.03	0.03	0.03	0.03	0.02	0.02	0.01	0.03	0.04	0.07	0.09	0.07
Per Share Metrics
Diluted EPS TTM	-0.91	-0.96	-1.00	-1.10	-1.05	-1.01	-1.14	-0.94	-0.92	-1.02	-1.36	-0.93
Free Cash Flow Per Share TTM	-1.03	-0.97	-1.08	-0.75	-0.71	-0.95	-1.02	-0.93	-0.66	-0.74	-0.98	-0.61
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	139.22%	130.42%	126.82%	133.85%	144.68%	176.29%	229.72%	139.75%	130.70%	125.40%	117.86%	122.93%
Operating Profit Margin TTM	-1,695.15%	-1,408.73%	-1,315.38%	-1,765.01%	-2,072.07%	-3,159.87%	-4,787.68%	-1,276.07%	-914.69%	-689.22%	-444.00%	-535.94%
Net Profit Margin TTM	-1,655.35%	-1,360.61%	-1,256.81%	-1,692.96%	-1,964.88%	-2,974.08%	-4,527.66%	-1,188.88%	-855.84%	-653.50%	-423.86%	-521.63%
Growth Metrics
Net Revenue Growth (1Y)	2.15%	106.65%	266.65%	-10.03%	-42.94%	-70.15%	-86.62%	-44.71%	-25.65%	-14.47%	55.52%	10.52%
Net Income Growth (1Y)	-13.94%	-5.46%	1.78%	28.12%	30.99%	35.83%	42.91%	26.01%	27.99%	33.28%	34.73%	26.89%
EPS Growth (1Y)	-14.08%	-5.63%	-12.17%	17.13%	14.53%	-0.62%	-16.29%	0.67%	-46.73%	-65.97%	-50.61%	-67.79%
Valuation Metrics
P/E TTM	-1.08	-1.06	-1.00	-1.66	-1.38	-1.36	-2.67	-5.31	-6.35	-7.78	-4.29	-2.75
P/B TTM	1.85	1.35	1.05	1.64	1.06	0.85	1.41	2.58	2.60	6.13	2.53	1.44
P/S TTM	17.91	14.36	12.57	28.05	27.02	40.48	120.90	63.14	54.39	50.86	18.17	14.34
Market Cap	127.35M	131.21M	129.78M	236.30M	188.11M	178.96M	340.45M	591.13M	663.54M	753.31M	382.45M	242.76M
Enterprise Value	43.23M	30.78M	4.87M	94.18M	45.98M	52.00M	188.80M	488.66M	446.80M	638.02M	274.10M	112.49M
Calculated Values
Free Cash Flow TTM	-133.21M	-125.46M	-140.23M	-97.24M	-92.64M	-123.79M	-114.65M	-110.58M	-74.70M	-70.05M	-64.50M	-57.66M
Net Debt	-84.12M	-100.43M	-124.90M	-142.12M	-142.13M	-126.96M	-151.65M	-102.47M	-216.74M	-115.30M	-108.34M	-130.28M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-23Purchase

Owner: Lynx1, Capital Management…

Title: -

Shares: 6,232

Price/Share: $0.90

Value: $5,608.80

Shares Owned: 8,019,148

Relationship: TenPercentOwner

Ownership: Indirect

2025-05-20Purchase

Owner: Lynx1, Capital Management…

Title: -

Shares: 1,200,000

Price/Share: $1.20

Value: $1,440,000.00

Shares Owned: 7,946,141

Relationship: TenPercentOwner

Ownership: Indirect

2024-12-13Purchase

Owner: Nichols, Weston, Lynx1 Ca…

Title: -

Shares: 100,000

Price/Share: $2.90

Value: $290,000.00

Shares Owned: 5,357,347

Relationship: TenPercentOwner

Ownership: Indirect

2024-11-15Purchase

Owner: Nichols, Weston, Lynx1 Ca…

Title: -

Shares: 947

Price/Share: $4.34

Value: $4,109.98

Shares Owned: 5,225,547

Relationship: TenPercentOwner

Ownership: Indirect

2024-09-23Purchase

Owner: Klencke, Barbara

Title: -

Shares: 5,000

Price/Share: $5.29

Value: $26,450.00

Shares Owned: 45,000

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-23	Lynx1, Capital Management…	TenPercentOwner	-	Indirect	Purchase	6,232	0.90	$5,608.80	8,019,148	4
2025-05-20	Lynx1, Capital Management…	TenPercentOwner	-	Indirect	Purchase	1,200,000	1.20	$1,440,000.00	7,946,141	4
2024-12-13	Nichols, Weston, Lynx1 Ca…	TenPercentOwner	-	Indirect	Purchase	100,000	2.90	$290,000.00	5,357,347	4
2024-11-15	Nichols, Weston, Lynx1 Ca…	TenPercentOwner	-	Indirect	Purchase	947	4.34	$4,109.98	5,225,547	4
2024-09-23	Klencke, Barbara	Director	-	Direct	Purchase	5,000	5.29	$26,450.00	45,000	4
2024-08-26	Klencke, Barbara	Director	-	Direct	Purchase	5,000	5.53	$27,650.00	40,000	4
2024-08-23	Zdraveski, Zoran	Officer	See Remarks	Direct	Sale	164,686	5.78	$951,885.08	4,716	4
2023-12-19	Barberich, Timothy J	Director	-	Direct	Purchase	317	4.97	$1,575.49	67,027	4
2023-12-14	Klencke, Barbara	Director	-	Direct	Purchase	5,000	5.08	$25,400.00	30,000	4
2023-06-02	Barberich, Timothy J	Director	-	Direct	Purchase	37,880	2.63	$99,624.40	37,880	4
2023-05-31	Lynx1, Capital Management…	TenPercentOwner	-	Indirect	Sale	25,400	2.51	$63,754.00	5,224,600	4
2022-12-28	Silver, Brian M.	Officer	Chief Financial Officer	Direct	Purchase	3,158	1.56	$4,926.48	32,885	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

24.55%

Inst. Shares: 31,888,948

Shares Outstanding: 129,913,376

2025-12-31

23.41%

Inst. Shares: 30,386,708

Shares Outstanding: 129,777,415

2025-09-30

26.58%

Inst. Shares: 34,512,738

Shares Outstanding: 129,835,938

2025-06-30

27.45%

Inst. Shares: 35,605,967

Shares Outstanding: 129,730,451

2025-03-31

30.82%

Inst. Shares: 39,966,399

Shares Outstanding: 129,678,572

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	31,888,948	129,913,376	24.55%
2025-12-31	30,386,708	129,777,415	23.41%
2025-09-30	34,512,738	129,835,938	26.58%
2025-06-30	35,605,967	129,730,451	27.45%
2025-03-31	39,966,399	129,678,572	30.82%
2024-12-31	41,422,330	111,990,417	36.99%
2024-09-30	41,686,320	118,700,362	35.12%
2024-06-30	41,404,110	113,425,357	36.50%
2024-03-31	34,161,509	94,875,893	36.01%
2023-12-31	31,795,128	65,599,858	48.47%
2023-09-30	28,560,559	94,829,844	30.12%
2023-06-30	27,810,140	47,208,664	58.91%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

TScan Therapeutics, Inc. (TCRX) — SEC Financial Statements & Analysis

TScan Therapeutics, Inc. (TCRX) is a biological products, (no diagnostic substances) company, incorporated in DE. TScan Therapeutics, Inc. trades on Nasdaq as: TCRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), TScan Therapeutics, Inc. reported a 2.15% year-over-year revenue growth, a Gross Profit Margin of 139.22% (TTM), a Debt-to-Equity ratio of 1.48x, a Price-to-Sales (P/S) ratio of 17.91x (TTM), a Price-to-Book (P/B) ratio of 1.85x (TTM), at a market cap of $127.35M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 2.15%
Gross Profit Margin TTM: 139.22%
Debt To Equity: 1.48x
P/S TTM: 17.91x
P/B TTM: 1.85x
Market Cap: $127.35M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is TScan Therapeutics, Inc. in?

TScan Therapeutics, Inc. (TCRX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is TCRX's market cap?

TScan Therapeutics, Inc. (TCRX) has a market capitalization of $127.35M as of 2026-06-30.

What exchange does TCRX trade on?

TScan Therapeutics, Inc. (TCRX) trades on the Nasdaq.

Where is TScan Therapeutics, Inc. incorporated?

TScan Therapeutics, Inc. is incorporated in DE.